

Doc Code:

PTO/SB/52 (09-04)

Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION DECLARATION BY THE ASSIGNEE		Docket Number (optional) 1718-0214P
I hereby declare that:		
The residence, mailing address and citizenship of the inventors are stated below.		
I am authorized to act on behalf of the following assignee: <u>MEDIVIR AB</u>		
and the title of my position with said assignee is: <u>CEO & President</u>		
The entire title to the patent identified below is vested in said assignee.		
Inventor <u>Johan HARMENBERG</u>	Citizenship <u>SWEDEN</u>	
Residence/Mailing Address <u>Karlvagen 94, S-115 22 Stockholm, SWEDEN</u>		
Inventor <u>Ana Harriet Margareta KRISTOFFERSON</u>	Citizenship <u>SWEDEN</u>	
Residence/Mailing Address <u>Majsterpevgatan 8, S-152 70 Sodertakle, SWEDEN</u>		
<input type="checkbox"/> Additional Inventors are named on separately numbered sheets attached hereto.		
Patent Number <u>6,337,324</u>	Date of Patent Issued <u>January 8, 2002</u>	
I believe said inventor(s) to be the original and first inventor(s) of the subject matter which is described and claimed in said patent, for which a reissue patent is sought on the invention entitled: <u>PHARMACEUTICAL COMBINATION</u>		
the specification of which		
<input type="checkbox"/> is attached hereto.		
<input checked="" type="checkbox"/> was filed on <u>February 2, 2004</u> as reissue application number <u>10 / 771,359</u> and was amended on _____		
(If applicable)		
I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.		
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.		
<input type="checkbox"/> I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b). Attached is form PTO/SB/02B (or equivalent) listing the foreign applications.		
I verily believe the original patent to be wholly or partly inoperative or invalid, for the reasons described below. (Check all boxes that apply.)		
<input type="checkbox"/> by reason of a defective specification or drawing.		
<input checked="" type="checkbox"/> by reason of the patentee claiming more or less than he had the right to claim in the patent.		
<input type="checkbox"/> by reason of other errors.		

[Page 1 of 2]

This collection of information is required by 37 CFR 1.175. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-8199 and select option 2.

Doc Code:

PTO/SB/52 (08-04)

Approved for use through 04/30/2007. OMB 0651-0033

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION DECLARATION BY THE ASSIGNEE		Docket Number (Optional) 1718-0214P
At least one error upon which reissue is based is described as follows: Claim 1 as granted may be anticipated by prior art not previously considered by the Examiner, specifically the reference Aoki et al., XP-001117608 Abstract, which is submitted with an IDS and PTO-1449 form. Aoki et al. disclose a composition of a combination of acyclovir and betamethasone and states that neither a beneficial nor a deleterious effect of topical glucocorticoid could be demonstrated. Accordingly, claim 1 has been amended to distinguish over Aoki et al.		
[Attach additional sheets, if needed.] All errors corrected in this reissue application arose without any deceptive intention on the part of the applicant.		
I hereby appoint:		
<input checked="" type="checkbox"/> Practitioners associated with Customer number:		02292
OR		
<input type="checkbox"/> Practitioner(s) named below:		
Name	Registration Number	
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.		
Correspondence Address: Direct all communications about the application to:		
<input checked="" type="checkbox"/> The address associated with Customer Number:		02292
OR		
<input type="checkbox"/> Firm or individual Name		
Address		
City	State	Zip
Country		
Telephone	Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.		
Signature 	Date 4 October 2005	
Full name of person signing (given name, family name) Lars Adlersson		
Address of Assignee Lunastigen 7, S-141 44 Huddinge, SWEDEN		

[Page 2 of 2]